Journal
FUTURE MICROBIOLOGY
Volume 14, Issue 2, Pages 89-110Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/fmb-2018-0233
Keywords
chronic HCV infection; chronic kidney disease; cirrhosis; glecaprevir; HCV; hepatitis C virus; HIV; NS3; 4A protease inhibitor; NS5A inhibitor; pibrentasvir
Categories
Funding
- AbbVie [NCT02243280, NCT02243293, NCT02446717, NCT02604017, NCT02640157, NCT02640482, NCT02636595, NCT02642432, NCT02738138, NCT02651194, NCT02692703]
- AbbVie
Ask authors/readers for more resources
In recent years, management of chronic hepatitis C virus (HCV) infection has been revolutionized by the availability of oral direct-acting antivirals (DAAs), which have significantly better efficacy and safety profiles than interferon-containing regimens. Simple, short-duration DAA therapies will facilitate expansion of HCV treatment to nonspecialist providers, which will be vital to achieve the WHO target of eliminating chronic HCV as a major public health threat by 2030. Coformulated glecaprevir/pibrentasvir is the only 8-week, pan-genotypic, 2-DAA regimen recommended by international guidelines as a first-line regimen in treatment-naive, noncirrhotic HCV genotype 1-6 patients. This review provides a comprehensive summary of the pharmacodynamic and pharmacokinetic parameters, efficacy, safety and place in the HCV treatment paradigm for glecaprevir/pibrentasvir.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available